Revenio Group Corporation: Changes in Boards of Revenio

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
122
Revenio Group Corporation: Changes in Boards of Revenio Group Corporation's subsidiaries

Revenio Group Corporation, Stock Exchange Release, January 2, 2017 at 15:00

CHANGES IN BOARDS OF REVENIO GROUP CORPORATION'S SUBSIDIARIES

The composition of the Board of Directors will change in Revenio Group Corporation's subsidiaries Icare Finland Oy, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.

As announced on 16 May 2016, Olli-Pekka Salovaara, Revenio Group Corporation's long-term President & CEO resigned on 31 December 2016. At the same time, he resigned from board membership in the above-mentioned subsidiaries.

Timo Hildén, who assumed the position of the Group's new President & CEO on 1 January 2017 and has been a deputy member on the boards of Icare Finland Oy, Revenio Research Oy and Done Medical Oy will become an ordinary member of these boards, and Robin Pulkkinen, the Group's CFO, will be appointed a deputy member of the boards. Tomi Karvo, Icare Finland Oy's Sales and Marketing Director, has been appointed a new member of Oscare Medical Oy's Board of Directors, and Timo Hildén has been appointed Chairman of the Board of Directors.

Revenio Group Corporation Timo Hildén President & CEO

For further information, please contact:

Timo Hildén, President & CEO, tel. +358 40 580 4774 timo.hilden@revenio.fi www.revenio.fi

DISTRIBUTION:

NASDAQ Helsinki Financial Supervisory Authority Principal media www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 28

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 25

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 64

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 192

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 31

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 216

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 328

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 195

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 13

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 16

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading

Top 5 Most Recently Viewed Articles

GM Partners with Barclays to Enhance Credit Card Offerings

Updated Category News Views 71

General Motors and Barclays Sign a Strategic Partnership General Motors (NYSE: GM) and Barclays have recently announced a significant long-term partnership that focuses on credit card services. This strategic agreement reflects both companies' commitment to enhancing customer experience and providing innovative financial solutions. Benefits of the New Credit Card...

Continue Reading
Enbridge Inc. Declares 3% Increase in Quarterly Dividend

Updated Category News Views 126

Enbridge Inc. Increases Quarterly Dividend by 3% Enbridge Inc. (TSX: ENB) has made a significant announcement regarding its quarterly dividend. The company declared a quarterly dividend of $0.9425 per common share, signaling a 3% increase from previous rates. This notable hike reflects Enbridge's commitment to shareholder value and marks the thirtieth consecutive year of...

Continue Reading
Jefferies Advises Caution on Biotech-Related CRO Investments

Updated Category News Views 545

CROs Confront Challenges as Biotech Market Slows In a recent analysis, Jefferies is advising investors to rethink their investments in contract research organizations (CROs), particularly those focused on biotech and early-stage research. This caution comes as the demand in the biotech sector has noticeably declined. Financial Struggles Affects Companies Jefferies has...

Continue Reading
Remarkable Cost Savings with QUELIMMUNE for Pediatric AKI

Updated Category News Views 137

Significant Economic Impact of QUELIMMUNE Therapy SeaStar Medical Holding Corporation (Nasdaq: ICU), a pioneering healthcare company, has recently published a health economic analysis that underscores the substantial financial benefits of its QUELIMMUNE therapy for pediatric patients suffering from Acute Kidney Injury (AKI). The analysis highlights an estimated average...

Continue Reading
SKF Invites Fans to Revitalize Tattoos with Brand Update

Updated Category News Views 228

SKF Invites Fans to Revitalize Tattoos with Brand Update SKF has taken an impactful step to modernize its brand identity, showcasing a fresh and dynamic look aimed at connecting with its audience more effectively. This update marks the company's first significant change to its logo since its inception in 1908, highlighting the dedication to innovation while respecting its...

Continue Reading